FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MDV IX LP 		2. Issuer Name and Ticker or Trading Symbol

Adamas Pharmaceuticals Inc [ ADMS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O MOHR DAVIDOW VENTURES, 3000 SAND HILL ROAD, SUITE 3-290 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/7/2015
(Street)

MENLO PARK, CA 94025
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/7/2015     S (1)    25737   D $27.5452   (2) 299749   I   MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.   (3)
Common Stock   7/8/2015     S (1)    3100   D $27.551   (4) 296649   I   MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.   (3)
Common Stock                  3772686   I   MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP   (5)
Common Stock                  265150   I   MDV VII, L.P.   (5)
Common Stock                  6043   I   MDV ENF VII (A), L.P.   (5)
Common Stock                  3146   I   MDV ENF VII (B), L.P.   (5)
Common Stock                  25661   I   MDV VII Leaders' Fund, L.P.   (5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by MDV IX on December 15, 2014.
( 2)  Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $27.50 and $27.84 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
( 3)  Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
( 4)  Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $27.50 and $27.72 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
( 5)  Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
MDV IX LP
C/O MOHR DAVIDOW VENTURES
3000 SAND HILL ROAD, SUITE 3-290
MENLO PARK, CA 94025
X

Seventh MDV Partners, L.L.C.
3000 SAND HILL ROAD
SUITE 3-290
MENLO PARK, CA 94025
X

Ninth MDV Partners, L.L.C.
3000 SAND HILL ROAD
SUITE 3-290
MENLO PARK, CA 94025
X

FEIBER JONATHAN D
3000 SAND HILL ROAD
SUITE 3-290
MENLO PARK, CA 94025
X

SCHOENDORF NANCY J
3000 SAND HILL ROAD
SUITE 3-290
MENLO PARK, CA 94025
X

MDV ENF VII (A), L.P.
3000 SAND HILL ROAD
SUITE 3-290
MENLO PARK, CA 94025
X

MDV ENF VII (B), L.P.
3000 SAND HILL ROAD
SUITE 3-290
MENLO PARK, CA 94025
X

MDV VII Leaders' Fund, L.P.
3000 SAND HILL ROAD
SUITE 3-290
MENLO PARK, CA 94025
X

MDV VII LP
C/O MOHR DAVIDOW VENTURES
3000 SAND HILL ROAD, SUITE 3-290
MENLO PARK, CA 94025
X


Signatures
Brett A. Teele 7/9/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Adamas Pharmaceuticals Charts.
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Adamas Pharmaceuticals Charts.